UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~November~~January 2923, ~~2018~~2019

Oncolix, Inc.

(Exact name of registrant as specified in its charter)

Florida	333-192405	46-3046340
(state or other jurisdictionof incorporation)	(CommissionFile Number)	(IRS EmployerIdentification Number)
(state or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

14405 Walters Road, Suite 780

Houston, TX

77014

(address of principal executive offices)

(zip code)

281-402-3167 (registrant’s telephone number, including area code)

___________________________________________ (~~registrant’s~~former ~~telephone~~name ~~number~~or former address, ~~including~~if ~~area~~changed ~~code~~since last report)

_____________________________________________

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 13.01 ~~Entry~~Notice ~~into~~of Delisting or Failure to Satisfy a ~~Material~~Continued ~~Definitive~~Listing ~~Agreement~~Rule or Standard; Transfer of Listing.

On January 23, 2019, Oncolix, Inc. (the Company) was notified by the OTCMarkets that its shares of common stock had a closing bid on OTCQB for 30 consecutive calendar days of less than $0.01, which violate the listing requirements for OTCMarkets. The ~~disclosure~~closing ~~set~~bid ~~forth~~of the Company’s common stock must be at or above $0.01 for 10 consecutive trading days prior to April 23, 2019, or the Company’s common stock will be delisted. Also, in ~~Item~~the 2event that the closing bid at any time falls below $0.04001, the common stock will be immediately delisted. In the event that the Company’s common stock is ~~incorporated~~delisted ~~herein~~from byOTCQB, ~~reference~~the Company expects its common stock to trade on the OTCPink.

Item 23.0302 ~~Creation~~Unregistered ofSales ~~a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement~~ of aEquity ~~Registrant~~Securities.

The disclosure set forth in Item 28.0401 is incorporated herein by reference.

~~Item~~The ~~2.04~~issuances ~~Triggering~~of ~~Events~~these ~~that~~securities ~~Accelerate~~did ornot ~~Increase~~involve athe ~~Direct~~payment ~~Financial~~of ~~Obligation~~any orsales ancommissions ~~Obligation~~and ~~under~~were anexempt ~~Off-Balance~~pursuant ~~Sheet~~to ~~Arrangement~~Section 4(a)(2) of the Securities Act of 1933.

~~Oncolix,~~Item ~~Inc., a Florida corporation (“Company”), has outstanding convertible notes in the principal amount of $~~5~~,407,757~~.02 ~~The~~Departure ~~Convertible Notes bear interest at a rate~~ of ~~10%~~Directors ~~per~~or ~~annum,~~Certain ~~with~~Ofﬁcers; ~~accrued~~Election ~~interest payable commencing April 1, 2019, then on the first day~~ of ~~each~~Directors; ~~calendar~~Appointment ~~month thereafter until maturity. The maturity~~ of ~~the~~Certain ~~Convertible~~Ofﬁcers; ~~Notes~~Compensatory isArrangements ~~August 1, 2019, but commencing on April 1, 2019 and on the first day~~ of ~~each~~Certain calendar month thereafter until maturity, the Company is required to redeem an amount of the Convertible Notes equal to 1/5th of the original principal amount, plus 10% of such monthly redemption amount as a bonusOfﬁcers.

On ~~November~~January 2911, ~~2018~~2019, ~~the~~Donald ~~Company~~Payne ~~entered~~resigned ~~into~~his aposition ~~variable~~as ~~rate,~~Secretary ~~convertible~~of ~~debt financing in~~ the ~~amount~~Company ofand ~~$83,000.~~provided ~~This~~written ~~financing~~notice ~~constituted~~of anhis ~~event~~intention ofto ~~default~~terminate ~~under~~his ~~the~~part-time ~~terms~~employment ofin ~~the~~35 ~~Convertible~~days. ~~Notes~~Mr. AtPayne ~~the~~has ~~holders’~~served ~~option,~~as ~~the~~a ~~principal~~part-time ~~amount,~~employee ~~accrued~~for ~~interest,~~several ~~and other amounts owing~~years, ~~shall immediately become due~~ and ~~payable.~~committed ~~The~~approximately ~~holders~~10% ~~have other rights (as a result~~ of ~~this~~his ~~event~~time ofto ~~default and~~ the ~~variable~~Company’s ~~rate,~~activities ~~convertible debt financing) as set forth~~ in ~~the~~late ~~securities~~2018. ~~purchase~~Mr. ~~agreement~~Payne ~~and~~also ~~Convertible~~served ~~Notes that have been filed~~ as ~~exhibits~~the toprincipal ~~Forms~~accounting ~~8-k~~officer ~~filed~~of ~~with~~ the ~~SEC~~Company onfrom ~~August~~April 9, 2017 ~~and~~to ~~June~~January ~~6, 2018~~2019.

Item 8.01 Other Events.

~~The~~In December 2018, the Company isengaged ~~halting~~a ~~enrollment~~consultant to assist it in ~~its~~analyzing ~~Phase~~financing Ialternatives ~~clinical~~for ~~trial~~the ofCompany. ~~Prolanta~~The ~~for~~Company has agreed to compensate the ~~treatment~~consultant through the issuance of ~~ovarian~~shares ~~cancer~~of Company common stock equal to up to 8% of fully diluted shares, subject to anti-dilution adjustments. As of December 17, 2018, such shares totaled approximately 62,000,000 shares, which shall vest and be issued as afollows: ~~result~~(i) 15,500,000 shares have vested; (ii) 15,500,000 shares shall vest and be issued on the 4th month anniversary date of ~~injection~~this ~~site~~agreement; ~~reactions~~(iii) at15,500,000 shares shall vest and be issued on the ~~current~~8th ~~dose~~month ~~level.~~anniversary Nodate ~~other~~of ~~adverse~~this ~~effects~~Agreement; orand ~~signs~~(iv) 15,500,000 shares shall vest and be issued on the 12th month anniversary date of ~~toxicity~~this agreement. The shares issued hereunder shall have ~~been~~anti-dilution ~~observed~~protection ~~for~~until the ~~drug~~earlier of (i) December 2018 and (ii) $3 million of debt or equity financing obtained by the Company after the date of this agreement. This consulting arrangement is terminable by either party upon 30 days’ written notice.

~~Two~~The ~~subjects~~estimated ~~enrolled~~shares inissuable under the ~~second~~agreement ~~dosing~~are ~~group,~~based 1on mgan ~~per~~estimated kg774 ofmillion ~~body~~fully ~~weight,~~diluted ~~have~~shares ~~experienced~~outstanding ~~inflammation~~as ~~and~~of ~~edema~~December at17, ~~the~~2018, ~~injection~~comprised ~~sites~~of ~~that~~114,227,936 ~~resulted~~shares inof ~~their~~common ~~withdrawal~~stock, ~~from~~63,038,284 ~~the~~shares ~~study.~~of ~~Prolanta~~Series isA ~~injected~~Preferred ~~subcutaneously~~Stock ~~daily~~(convertible ~~during~~into ~~the~~approximately ~~treatment~~143,000,000 ~~period.~~shares ~~The~~of ~~Company~~common ~~believes~~stock), ~~that~~and awarrants ~~reformulation~~and orconvertible ~~alternative~~notes ~~dosing~~for ~~method~~the ofremainder. ~~the~~As ~~drug~~previously ~~will~~disclosed, bethe ~~required~~Company’s toconvertible ~~continue~~notes ~~the~~are ~~clinical~~currently ~~evaluation~~due ofand the ~~drug,~~conversion ~~and~~rate of such ~~changes~~debt ~~may~~fluctuates ~~require~~at ~~additional~~a ~~preclinical~~discount ~~toxicity~~to ~~studies~~the ~~and~~market ~~additional~~price. ~~clearance~~As bya ~~the~~result, ~~U.S.~~as ~~Food~~conversions ~~and~~of ~~Drug~~such ~~Administration.~~notes ~~The~~occur, ~~Company~~substantial ~~does~~additional ~~not~~dilution ~~have~~may occur if the ~~financial~~conversion ~~resources~~rate atis ~~this~~based ~~time~~on tocommon ~~conduct~~stock ~~such~~prices ~~additional~~below ~~studies~~$0.03.

~~The Company will evaluate its development plans, including accelerating its development timelines for CycloSam, its other product candidate.~~ 2

~~Item 9.01 Financial Statements and Exhibits~~SIGNATURES

~~(b)~~Pursuant ~~Exhibits.~~to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

10.1	Securities Purchase Agreement by and between the Company and Power-Up Lending Group, Ltd., dated 11/27/2018
	Oncolix, Inc.
10.2	Convertible Promissory Note by and between the Company and Power-Up Lending Group, Ltd., dated 11/27/2018
Dated: January 28, 2019	/s/ Michael T. Redman
	Michael T. Redman
	Chief Executive Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	Oncolix, Inc.
Dated: January 2, 2019	By:	/s/ Michael T. Redman
		Michael T. Redman
		Chief Executive Officer

Filing Compare · Oncolix, Inc.